N
CYT

Nuveen’s Cyteir Therapeutics, Inc. Common Stock CYT Stock Holding History

Nuveen’s Portfolio CYT Stock Details CYT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-10,992
Closed -$48K – 3549
2022
Q1 		$48K Hold
10,992
– – ﹤0.01% 3278
2021
Q4 		$124K Hold
10,992
– – ﹤0.01% 3273
2021
Q3 		$193K Buy
+10,992
New +$205K ﹤0.01% 3279

Other funds holding CYT

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
OMC
OUP Management Company Bala Cynwyd, Pennsylvania $44.5M AUM 55.11% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Nuveen's CYT Position: Q2 2022 in Review

Nuveen sold out of Cyteir Therapeutics, Inc. Common Stock (CYT) in Q2 2022, closing a stake of 10,992 shares — an estimated $48K sold.

Nuveen first reported a position in CYT in Q3 2021 and held it in 3 quarters. The position peaked at $193K in Q3 2021. 45 funds tracked by Wall St. Rank hold CYT as of Q2 2022.

  • Nuveen reported no remaining Cyteir Therapeutics, Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Nuveen sold 10,992 Cyteir Therapeutics, Inc. Common Stock shares in Q2 2022, an estimated $48K.
  • Nuveen first reported a position in Cyteir Therapeutics, Inc. Common Stock in Q3 2021 and held it in 3 quarters.
  • Nuveen's Cyteir Therapeutics, Inc. Common Stock position peaked at $193K in Q3 2021.
  • 45 funds tracked by Wall St. Rank held Cyteir Therapeutics, Inc. Common Stock as of Q2 2022.

Based on Nuveen's 13F filing for Q2 2022, filed 15 Aug 2022.